News

Thursday, 26. January 2012

Antisense Pharma presents at German Science Day to business and daily press, plus investors

The German Science Day is to present the major research and development contribution of German biotechnology companies working on cancer. The all-day event takes place on February 2nd 2012 at the Charité, Berlin. more

Wednesday, 11. January 2012

Antisense Pharma terminates Phase III trial SAPPHIRE (HGG 2nd line) due to slow patient recruitment

Instead Antisense Pharma will pursue 1st line treatment of GBM and pancreatic cancer patients. The planned Phase II trial with trabedersen in 2nd line pancreatic cancer is on track and will start in 2012.  mehr

Wednesday, 11. January 2012

Special Issue: Transforming Growth Factor Beta (TGF-β) as a Target in Oncology

Current Pharmaceutical Biotechnology has published reviews from more than 25 internationally renowned TGF-β experts. Antisense Pharma’s founder, Dr. Karl-Hermann Schlingensiepen, was entrusted with guest editor ship.  mehr

Tuesday, 01. November 2011

New aspects of trabedersen in HGG patients to be presented at 16th SNO annual meeting in California, USA

Antisense Pharma's poster 'Response Patterns of High-grade Glioma Patients treated with the TGF-β2 Inhibitior Trabedersen in a Randomized Phase IIb Study will be presented by Dr. Hau, University Regensburg, on November 19th.  mehr

Thursday, 13. October 2011

Oral presentation at EuroTIDES 2011 in Berlin, Germany

On November 16, 2011, Dr. Peter Kießling, Head of Clinical Research at Antisense Pharma, will be presenting latest clininal results with the TGF-β2 inhibitor trabedersen in pancreatic carcinoma and malignant melanoma.  mehr